Pacira BioSciences (PCRX) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Pacira BioSciences (PCRX) over the last 15 years, with Q3 2025 value amounting to $0.52.
- Pacira BioSciences' Debt to Equity rose 2587.41% to $0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.52, marking a year-over-year increase of 2587.41%. This contributed to the annual value of $0.75 for FY2024, which is 42836.37% up from last year.
- According to the latest figures from Q3 2025, Pacira BioSciences' Debt to Equity is $0.52, which was up 2587.41% from $0.4 recorded in Q2 2025.
- Over the past 5 years, Pacira BioSciences' Debt to Equity peaked at $0.94 during Q4 2021, and registered a low of $0.12 during Q2 2024.
- In the last 5 years, Pacira BioSciences' Debt to Equity had a median value of $0.37 in 2022 and averaged $0.37.
- As far as peak fluctuations go, Pacira BioSciences' Debt to Equity tumbled by 7183.99% in 2023, and later soared by 42836.37% in 2024.
- Over the past 5 years, Pacira BioSciences' Debt to Equity (Quarter) stood at $0.94 in 2021, then crashed by 60.87% to $0.37 in 2022, then plummeted by 61.26% to $0.14 in 2023, then surged by 428.36% to $0.75 in 2024, then crashed by 31.11% to $0.52 in 2025.
- Its Debt to Equity was $0.52 in Q3 2025, compared to $0.4 in Q2 2025 and $0.38 in Q1 2025.